相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Diadenosine Homodinucleotide P18 Improves In Vitro Myelination in Experimental Charcot-Marie-Tooth Type 1A
Lucilla Nobbio et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2014)
Animal Models and Therapeutic Prospects for Charcot-Marie-Tooth Disease
Delphine Bouhy et al.
ANNALS OF NEUROLOGY (2013)
High-Dosage Ascorbic Acid Treatment in Charcot-Marie-Tooth Disease Type 1A Results of a Randomized, Double-Masked, Controlled Trial
Richard A. Lewis et al.
JAMA NEUROLOGY (2013)
Identification of Drug Modulators Targeting Gene-Dosage Disease CMT1A
Sung-Wook Jang et al.
ACS CHEMICAL BIOLOGY (2012)
Murine therapeutic models for Charcot-Marie-Tooth (CMT) disease
Robert Fledrich et al.
BRITISH MEDICAL BULLETIN (2012)
Inherited Neuropathies
Angelo Schenone et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2011)
Mouse Schwann Cells Need Both NRG1 and Cyclic AMP to Myelinate
Peter Arthur-Farraj et al.
GLIA (2011)
Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial
Davide Pareyson et al.
LANCET NEUROLOGY (2011)
Copy number variation upstream of PMP22 in Charcot-Marie-Tooth disease
Marian A. J. Weterman et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2010)
PMP22 expression in dermal nerve myelin from patients with CMT1A
Istvan Katona et al.
BRAIN (2009)
Peripheral Myelin Protein 22 is Regulated Post-Transcriptionally by miRNA-29a
Jonathan D. Verrier et al.
GLIA (2009)
Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial
Joshua Burns et al.
LANCET NEUROLOGY (2009)
A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL):: The study protocol [EudraCT no.: 2006-000032-27]
Davide Pareyson et al.
PHARMACOLOGICAL RESEARCH (2006)
Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside
J Li et al.
BRAIN (2005)
Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease
E Passage et al.
NATURE MEDICINE (2004)
Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A)
MW Sereda et al.
NATURE MEDICINE (2003)
Molecular dissection of the Schwann cell specific promoter of the PMP22 gene
D Sabéran-Djoneidi et al.
GENE (2000)
分享论文
